Skip to main content

Articles By Jack Cush, MD


Does Methotrexate Work in Alopecia Universalis?

08 March 2023

Alopecia areata totalis (AT) and universalis (AU) are the most severe and difficult to treat forms of alopecia areata (AA).

Read Article

Does Biologic Treatment in Psoriasis Reduce the Risk of Psoriatic Arthritis?

07 March 2023

Retrospective claims analysis shows that psoriasis patients treated with either an IL-12/23 inhibitor or an IL-23 inhibitor had a lower risk of developing incident psoriatic arthritis, compared to TNF inhibitors or IL-17 inhibitors.

Read Article

Long-Term Benefit of Rituximab in Systemic Sclerosis

06 March 2023

A small cohort trial of rituximab (RTX) in 29 systemic sclerosis patients showed significantly improved skin sclerosis and lung function after a follow-up of 96 weeks.

Read Article
RheumNow Podcast square

NSAIDs in Pregnancy (3.3.2023)

03 March 2023

Dr. Jack Cush reviews the lastest journal articles, news, and FDA announcements from the past week on RheumNow.  This week, the importance of IFNa, Subclinical PsA and NSAID safety during Pregnancy.

Read Article

VEGA - The Efficacy of Combination Biologics in Ulcerative Colitis

02 March 2023

A novel trial has shown that combination biologic therapy (guselkumab plus golimumab) to be more effective in ulcerative colitis than either biologic alone.

Read Article

Sarilumab is FDA Approved for PMR

01 March 2023

Yesterday, the U.S. Food and Drug Administration (FDA) approved sarilumab (Kevzara) for the treatment of adults with active, refractory polymyalgia rheumatica (PMR), stipulating it is indicated in those patients who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.

Read Article

Treat-to-Target Guidelines for GCA and PMR

28 February 2023

The Annals of Rheumatic Disease has published updated multinational, treat-to-target (T2T) recommendations for the treatment of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR).

Read Article

Phase 3 Trials of Baricitinib Disappoint in SLE

27 February 2023

Despite the encouraging phase II trial results of baricitinib in systemic lupus erythematosus (SLE) patients, two parallel phase III trials have failed to redemonstrate the efficacy of baricitinib in active SLE, thereby halting development of baricitinib in SLE. 

Read Article
RheumNow Podcast square

The Late Edition (2.24.2023)

24 February 2023

Dr. Jack Cush reviews the news and journal articles from the past week on

Read Article

Periodontal Mucosal Breaks Trigger RA Disease Activity

23 February 2023

Periodontal disease (PD) is more common in rheumatoid arthritis (RA), especially those with anti-citrullinated protein antibodies (ACPAs).  RA activity has been linked to the severity of PD and mucosal inflammation.

Read Article